Role of Inositol 1,4,5-Trishosphate Receptors in Pathogenesis of Huntington's Disease and Spinocerebellar Ataxias

被引:72
作者
Bezprozvanny, Ilya [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
Calcium signaling; Huntingtin; Neurodegeneration; Polyglutamine expansion; Inositol 1,4,5-trisphosphate; Ataxin-2; Ataxin-3; Spinocerebellar ataxias; Transgenic mice; NMDA receptor; Apoptosis; Mitochondria; Memantine; LENGTH MUTANT HUNTINGTIN; POLYGLUTAMINE-INDUCED NEURODEGENERATION; DOMINANT CEREBELLAR ATAXIAS; MESSENGER-RNA EXPRESSION; HIPPOCAMPAL CA1 NEURONS; LONG-TERM DEPRESSION; PROTEIN-KINASE-C; YAC MOUSE MODEL; 1,4,5-TRISPHOSPHATE RECEPTOR; NMDA RECEPTORS;
D O I
10.1007/s11064-010-0393-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Huntington's disease (HD) and spinocerebellar ataxias (SCAs) are autosomal-dominant neurodegenerative disorders. HD is caused by polyglutamine (polyQ) expansion in the amino-terminal region of a protein huntingtin (Htt) and primarily affects medium spiny striatal neurons (MSN). Many SCAs are caused by polyQ-expansion in ataxin proteins and primarily affect cerebellar Purkinje cells. The reasons for neuronal dysfunction and death in HD and SCAs remain poorly understood and no cure is available for the patients. Our laboratory discovered that mutant huntingtin, ataxin-2 and ataxin-3 proteins specifically bind to the carboxy-terminal region of the type 1 inositol 1,4,5-trisphosphate receptor (IP(3)R1), an intracellular Ca2+ release channel. Moreover, we found that association of mutant huntingtin or ataxins with IP(3)R1 causes sensitization of IP(3)R1 to activation by IP3 in planar lipid bilayers and in neuronal cells. These results suggested that deranged neuronal Ca2+ signaling might play an important role in pathogenesis of HD, SCA2 and SCA3. In support of this idea, we demonstrated a connection between abnormal Ca2+ signaling and neuronal cell death in experiments with HD, SCA2 and SCA3 transgenic mouse models. Additional data in the literature indicate that abnormal neuronal Ca2+ signaling may also play an important role in pathogenesis of SCA1, SCA5, SCA6, SCA14 and SCA15/16. Based on these results I propose that IP3R and other Ca2+ signaling proteins should be considered as potential therapeutic targets for treatment of HD and SCAs.
引用
收藏
页码:1186 / 1197
页数:12
相关论文
共 147 条
[1]
Enzymological analysis of mutant protein kinase Cγ causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis [J].
Adachi, Naoko ;
Kobayashi, Takeshi ;
Takahashi, Hideyuki ;
Kawasaki, Takumi ;
Shirai, Yasuhito ;
Ueyama, Takehiko ;
Matsuda, Toshio ;
Seki, Takahiro ;
Sakai, Norio ;
Saito, Naoaki .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (28) :19854-19863
[2]
Structural and functional analysis of ataxin-2 and ataxin-3 [J].
Albrecht, M ;
Golatta, M ;
Wüllner, U ;
Lengauer, T .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (15) :3155-3170
[3]
Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease [J].
Ali, Noore J. ;
Levine, Michael S. .
DEVELOPMENTAL NEUROSCIENCE, 2006, 28 (03) :230-238
[4]
Dopamine and Glutamate in Huntington's Disease: A Balancing Act [J].
Andre, Veronique M. ;
Cepeda, Carlos ;
Levine, Michael S. .
CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (03) :163-178
[5]
BEAL MF, 1991, J NEUROSCI, V11, P1649
[6]
REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[7]
Use of antihypertensives and the risk of Parkinson disease [J].
Becker, Claudia ;
Jick, Susan S. ;
Meier, Christoph R. .
NEUROLOGY, 2008, 70 (16) :1438-1444
[8]
Neuronal calcium signaling [J].
Berridge, MJ .
NEURON, 1998, 21 (01) :13-26
[9]
Deranged neuronal calcium signaling and Huntington disease [J].
Bezprozvanny, I ;
Hayden, MR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 322 (04) :1310-1317
[10]
THERAPEUTIC PROSPECTS FOR SPINOCEREBELLAR ATAXIA TYPE 2 AND 3 [J].
Bezprozvanny, I. ;
Klockgether, T. .
DRUGS OF THE FUTURE, 2009, 34 (12) :991-999